Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Arrowhead Publishers

Drug Delivery Technologies Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies
The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

Cancer Therapeutics Market Insight and R&D Pipeline Analysis
The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail the markets for colorectal cancer, prostate cancer, lung cancer, breast cancer, leukemia and non-Hodgkin’s lymphoma. Therapies for other types of cancer are discussed throughout the report, but are limited to the Company Briefs chapter and various tables throughout the report. This report from Arrowhead Publishers examines these major cancer markets in light of newly emerging therapeutics, shifting market shares and line extensions for major products on the market.

Evidence-Based Medicine Current Use and Future Impact on Global Clinical and Reimbursement Practices
Evidence-based medicine is defined as an attempt to use standards from scientifically-collected evidence to improve medical practices by assessing risks and benefits of treatments and/or the lack of treatments. The term can be taken to cover a wide variety of recommendations and guidelines, as well as the basis for decisions regarding pharmaceutical reimbursement. This one-of-a-kind report discusses evidence-based medicine in a variety of its guises, illustrating the pervasive nature of evidence-based decisions in healthcare and pharmaceutical environments.

Indian Generics 2008-2012 The Growing Threat to Westernised Markets
Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world. Several leading Indian pharmaceutical companies have applied themselves to the challenge of entering Western markets with great success. These companies now present a very serious threat to the existing Western generic companies in their domestic markets as they take ever-larger market shares and increase the levels of competition.

The Global Pain Therapeutics Market, 3rd Edition Market Analysis, R&D Pipelines and Competitive Landscape
One in five people suffer from moderate to severe chronic pain, and one in three is unable or less able to maintain an independent lifestyle due to their pain. Between 50 and 60 percent of people with chronic pain are less able or unable to exercise, sleep normally, perform household chores, attend social activities, drive a car, or walk.

The value of the pharmaceutical market for pain relief in 2008 reflects this seeming worldwide epidemic of pain. The Global Pain Therapeutics Market assesses key pain management therapeutics - such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain. This report discusses the key products within each of these areas and outlines the drivers of these markets as well as the restraints on them.

The Global Antibacterials Market R&D Pipelines Market Analysis and Competitive Landscape
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape
The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).

According to Arrowhead Publishers’ new report The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral market is set to grow to over US$25.0 billion by 2012 driven by the uptake of newer anti-retroviral agents in combination therapy and the launch of ten new products for the treatment of HIV and hepatitis which will address the need of treatment-resistant patients. This will help to stem the tide of this prevalent and often lethal killer in our society today.

A Global Analytical Guide and Comparative Analysis of International Destinations with Location Attractiveness Index
Offshoring clinical trials to emerging markets around the world is receiving increasing attention as a very attractive alternative in the clinical development process. This follows as a natural reaction to already successful offshoring activities in the IT industry. The big question is: Do clinical research capabilities comparable to the US in terms of sophistication and FDA-compliance exist anywhere else in the world? And if they do, are they ready to handle the huge surge in business likely headed their way?

Innovations and Trends in Clinical Trials Microdosing (Phase 0 Trials) Adaptive Trials Phase IV Trials and the Role of Information Technology
The clinical trials industry has clear potential for strong growth in the future, driven by technological and scientific advances. This trend is complemented by the development of new trial designs, with a view to rationalizing and accelerating the drug discovery process by identifying failures at an earlier stage.

The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007
With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An increase in the number of aged people, increased life expectancy, unmet clinical needs together with advances in treatments of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease will continue to contribute to the expansion of the global market.

Monoclonal Antibodies 2007
In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. This share increased substantially since 2001, when it barely surpassed 13 percent. Monoclonal antibody (MAbs) therapies have been posting the fastest growth within the protein therapeutics market. According to Arrowhead Publishers’ report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight the value of this market is set to reach more than $16 billion in 2006This growth will continue in the coming years, boosted by a number of new MAbs on the market, new indications for successful medications, and their ability to treat conditions and diseases for which there is great unmet need.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions